Cell therapy weekly: Acquisitions for Scientific Industries and BioLife Solutions
This week: Scientific Industries acquires aquila biolabs, Mogrify closes Series A2 funding at US$16 million and BioLife Solutions completes acquisition of Stirling Ultracold.
The news highlights:
- Scientific Industries acquires aquila biolabs
- Mogrify closes Series A2 funding at US$33 million
- BioLife Solutions acquires Stirling Ultracold
Scientific Industries acquires aquila biolabs
Scientific Industries (NY, USA) has announced its acquisition of aquila biolabs (Baesweiler, Germany), enabling both organizations’ experience in smart sensing technologies to advance a digital, sensor-based platform to optimize, simplify and accelerate bioprocessing workflows.
John Moore, SBI’s President and Chairman of Scientific Industries, said, “The combined technologies from these two companies will allow us to create a new digital platform that brings dramatic innovation and significantly enhance accuracy in and throughput to the biopharmaceutical workflow…the ability to precisely tune multiple culture parameters is essential for efficient, consistent production of high-quality therapeutics.”
“We are excited to join SBI and expand the reach of our unique platform to bioprocess scientists around the world,” said Daniel Grünes, co-founder of aquila biolabs who will assume the role of vice president of R&D and Operations at SBI. “While customers already have access to some process parameters, there are still too many black boxes and unknowns in bioprocessing. Our platform combined with SBI will deliver actionable insights to our customers to help them make the right decisions.”
Mogrify closes Series A2 funding at US$16 million
Mogrify (Cambridge, UK) has raised US$16million in their Series A2 funding round, bringing their total raised to date to US$33 million. Mogrify, which aims to transform the development of cell therapy using direct cellular conversion, will use the funding to grow their internal programs as well as develop and out-license novel IP relating to cell conversation. The funding will also see Mogrify’s headcount expand to 60.
Alice Newcombe-Ellis, Founder and Managing Partner, Ahren Innovation Capital, said: “Mogrify’s technology is well positioned to disrupt the global cell therapy market. The Company has grown rapidly since February, appointing a world-class management team and delivering strongly against its business plans. We look forward to supporting Mogrify as it continues to go from strength to strength.”
BioLife Solutions acquires Stirling Ultracold
BioLife Solutions, Inc. (WA, USA) has announced that it has closed its acquisition of Stirling Ultracold (OH, USA). The news comes as Stirling Ultracold was named as a preferred provider for a leading global biopharma contract development and manufacturing organization (CDMO) and will supply 100 freezers, bringing this CDMO’s capacity to 300 Stirling freezers worldwide.
Mike Rice, BioLife CEO, commented, “We welcome Dusty Tenney in his new role as BioLife’s president and chief operating officer. Dusty and the entire Stirling team continue to deliver innovative solutions and stellar support to cell and gene therapy developers and contract manufacturing companies. We are realizing the cross-selling leverage we anticipated via our M&A strategy, as this customer uses our entire bioproduction tools and services portfolio….We see a tremendous opportunity to cross-sell our entire bioproduction tools and services portfolio to companies in the cell and gene therapy and broader biopharma markets.”
You might also like:
